Main Article Content
Biologics, Dupilumab, Drug Reaction
Atopic dermatitis (AD) is a common inflammatory skin condition. The newly FDA approved biologic dupilumab has demonstrated significant improvement in the signs and symptoms of AD, including pruritus as well as those of anxiety and depression1. The most frequently reported adverse effects of dupilumab include injection site reactions, nasopharyngitis, upper respiratory infections, and conjunctivitis 1-5. We report a case of dupilumab-induced psoriasiform dermatitis. To our knowledge, there have been no reports to date of a dupilumab-induced psoriasiform dermatitis. There has been one report of an erythrodermic presentation of psoriasis in a patient treated with dupilumab8. As novel immunotherapy treatments are developed and employed in the treatment of common conditions such as AD, it is important to better understand and be aware of the potential side effects and immune-based sequelae that may arise in addition to available treatment options for these adverse reaction.
Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials. J Am Acad Dermatol, 2018. 78(1): p. 62-69 e1.
Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy, 2015. 7(10): p. 1043-58.
Sidbury R, TOm WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol, 2014. 71(6): p. 1218-33.
Vangipuram R, Tyring SK. Dupilumab for Moderate-to-Severe Atopic Dermatitis. Skin Therapy Lett, 2017. 22(6): p. 1-4.
Simpson EL, Bieber R, Guttman-Yassky Emma. et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med, 2016. 375(24): p. 2335-2348.
Blauvelt A, de Bruin-Weller, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet, 2017. 389(10086): p. 2287-2303.
Tracey EH, Elston C, Peasel P, et al. Erythrodermic presentation of psoriasis in a patient treated with dupilumab. JAAD Case Rep, 2018. 4(7): p. 708-710.
Toussirot E, Aubin F. Paradoxical reactions under TNF-alpha blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open, 2016. 2(2): p. e000239.